| ||||||||||
| Rating | Health Concerns |
|---|---|
![]() |
|
Reliable and relatively consistent scientific data showing a substantial health benefit. Contradictory, insufficient, or preliminary
studies suggesting a health benefit or minimal health benefit. For an herb, supported by traditional use but
minimal or no scientific evidence. For a supplement, little scientific support and/or minimal
health benefit. | |
A deficiency can be the result of diseases that increase the need for glutathione, deficiencies of the amino acids needed for synthesis, or diseases that inhibit glutathione formation.27 Examples of some health conditions that are associated with glutathione deficiency include diabetes, low sperm counts, liver disease, cataracts, and HIV infection, respiratory distress syndrome, cancer, and idiopathic pulmonary fibrosis. Cigarette smoking is also associated with low glutathione levels because it increases the rate of utilization of glutathione.
There is very little evidence that taking glutathione supplements provides any benefit, despite promising evidence about the effects of aerosol, intravenous, and intramuscular glutathione, for people with a wide variety of conditions. People who have a proven glutathione deficiency, which may require administration of glutathione intravenously, intramuscularly, or by aerosol, should be treated by a healthcare professional. All ovarian cancer patients currently taking cisplatin (Platinol®) should discuss using intravenous glutathione with a healthcare professional.
No side effects or interactions are known with oral administration of glutathione.
Are there any drug
interactions?
Certain medicines may interact with glutathione. Refer to drug interactions for a list of those medicines.
1. Sen CK. Nutritional biochemistry of cellular glutathione. Nutr Biochem 1997;8:660-72.
2. Flagg EW, Coates RJ, Jones DP, et al. Dietary glutathione intake and the risk of oral and pharyngeal cancer. Am J Epidemiol 1994;139:453-65.
3. Donnerstag B, Ohlenschläger, Cinatl J, et al. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Lett 1996;110:63-70.
4. Trickler D, Shklar G, Schwartz J. Inhibition of oral carcinogenesis by glutathione. Nutr Cancer 1993;20:139-44.
5. Julius M, Lang C, Gleiberman L, et al. Glutathione and morbidity in a community-based sample of elderly. J Clin Epidemiol 1994;47:1021-6.
6. Hagen TM, Wierzbicka GT, Sillau AH, et al. Fate of dietary glutathione: disposition in the gastrointestinal tract. Am J Physiol 1990;259(4Pt1):G530-5.
7. Favilli F, Marraccini P, Iantomasis T, Vincenzini MT. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br J Nutr 1997;78:293-300.
8. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol 1992;43:667-9.
9. Hunjan MK, Evered DF. Absorption of glutathione from the gastro-intestinal tract. Biochim Biophys Acta 1985;815:184-8.
10. Johnston CS, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione in healthy adults. Am J Clin Nutr 1993;58:103-5.
11. Bunin AIa, Filina AA, Erchev VP. A glutathione deficiency in open-angle glaucoma and the approaches to its correction. Vestn Oftalmol 1992;108:13-5 [in Russian].
12. Amores-Sanchez MI, Medina MA. Glutamine, as a precursor of glutathione, and oxidative stress. Mol Genet Metab 1999;67:100-5.
13. Wang ST, Chen HW, Sheen LY, Lii CK. Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr 1997;127:2135-41.
14. Vendemiale G, Altomare E, Trizio T, et al. Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol 1989;24:407-15.
15. Bounous G, Gervais F, Amer V, et al. The influence of dietary whey protein on tissue glutathione and the diseases of aging. Clin Invest Med 1989;12:343-9.
16. Molloy J, Martin JF, Baskerville PA, et al. S-nitrosoglutathione reduces the rate of embolization in humans. Circulation 1998;98:1372-5.
17. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997;8:569-73.
18. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32.
19. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1159-70.
20. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 1991;81:739-42.
21. Lenzi A, Picardo M, Gandini L, et al. Glutathione treatment of dyspermia: effect on the lipoperoxidation process. Hum Reprod 1994;9:2044-50.
22. Lenzi A, Culasso F, Gandini L, et al. Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. Hum Reprod 1993;8:1657-62.
23. Testa B, Mesolella M, Testa D. Glutathione in the upper respiratory tract. Ann Otol Rhinol Laryngol 1995;104:117-9.
24. Dalhoff K, Ranek L, Mantoni M, Poulsen HE. Glutathione treatment of hepatocellular carcinoma. Liver 1992;12:341-3.
25. Garcia-Giralt E, Perdereau B, Brixy F, et al. Preliminary study of glutathione, L-cysteine and anthocyans (Recancostat Compositum™) in metastatic colorectal carcinoma with malnutrition. Seventh International Congress on Anti-Cancer Treatment, February 3-6, 1996, Paris, France.
26. Jones DP, Coates RJ, Flagg EW, et al. Glutathione in foods listed in the National Cancer Institutes Health Habits and History Food Frequency Questionnaire. Nutr Cancer 1995;17:57–75.
27. White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human disease. J Nutr Biochem 1994;5:218–26.
| |||||||